[February 23, 2017]

Global Berylliosis (Chronic Beryllium Disease) API Manufacturers, Marketed and Phase III Drugs Landscape Report 2017-2018 - Research and Markets

Research and Markets has announced the addition of the "Berylliosis (Chronic Beryllium Disease) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" drug pipelines to their offering.

Berylliosis (Chronic Beryllium Disease) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Berylliosis (Chronic Beryllium Disease) Report is to understand the market and pipeline status of the drugs around the Berylliosis (Chronic Beryllium Disease) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designng pipeline strategies. The Report provides the historical and forecasted sales of the drugs till 2018.

The Berylliosis (Chronic Beryllium Disease) Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Berylliosis (Chronic Beryllium Disease).

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Berylliosis (Chronic Beryllium Disease)

7. Phase III Drugs for Berylliosis (Chronic Beryllium Disease)

8. Discontinued Drugs for Berylliosis (Chronic Beryllium Disease)

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/b7r9lw/berylliosis

View source version on businesswire.com: http://www.businesswire.com/news/home/20170223006634/en/

[ Back To TMCnet.com's Homepage ]